Top

Published in:

Open Access 01-12-2019 | NSCLC | Correction

Correction to: High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer

Authors: Wenwu Xiao, Weijie Ma, Sixi Wei, Qianping Li, Ruiwu Liu, Randy P. Carney, Kevin Yang, Joyce Lee, Alan Nyugen, Ken Y. Yoneda, Kit S. Lam, Tianhong Li

Published in: Journal of Hematology & Oncology | Issue 1/2019

Excerpt

Correction to: J Hematol Oncol (2019) 12:56 …

Xiao W, Ma W, Wei S, Li Q, Liu R, Carney RP, et al. High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer. J Hematol Oncol. 2019;12:56 https://doi.org/10.1186/s13045-019-0740-7.CrossRef

Title: Correction to: High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer
Authors: Wenwu Xiao
Weijie Ma
Sixi Wei
Qianping Li
Ruiwu Liu
Randy P. Carney
Kevin Yang
Joyce Lee
Alan Nyugen
Ken Y. Yoneda
Kit S. Lam
Tianhong Li
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: NSCLC
NSCLC
Published in: Journal of Hematology & Oncology / Issue 1/2019
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-019-0764-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2019

Super-enhancers: critical roles and therapeutic targets in hematologic malignancies

Target selection for CAR-T therapy

Correction to: Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells

Immune cell therapy for hepatocellular carcinoma

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma

DLL3: an emerging target in small cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer